1. A PHASE I STUDY OF IBRUTINIB COMBINED WITH RITUXIMAB, IFOSFAMIDE, CARBOPLATIN, AND ETOPOSIDE IN PATIENTS WITH RELAPSED OR PRIMARY REFRACTORY DIFFUSE LARGE B‐CELL LYMPHOMA. (June 2017) Authors: Sauter, C.S.; Matasar, M.J.; Schoder, H.; Drullinsky, P.; Gerecitano, J.; Kumar, A.; Noy, A.; Palomba, M.L.; Portlock, C.S.; Straus, D.J.; Zelenetz, A.D.; McCall, S.S.; Miller, S.T.; Courtien, A.I.; Younes, A.; Moskowitz, C.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 265 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. A PILOT STUDY OF BRENTUXIMAB VEDOTIN AND AVD CHEMOTHERAPY FOLLOWED BY 20 GY INVOLVED‐SITE RADIOTHERAPY IN EARLY STAGE, UNFAVORABLE RISK HODGKIN LYMPHOMA. (June 2017) Authors: Kumar, A.; Casulo, C.; Advani, R.; Budde, E.; Barr, P.M.; Batlevi, C.L.; Chen, R.; Constine, L.S.; Courtien, A.I.; Dandapani, S.V.; Drullinsky, P.; Friedberg, J.W.; Hamlin, P.A.; Hoppe, R.T.; Matasar, M.J.; McArthur, G.N.; Miller, S.T.; Moskowitz, A.J.; Noy, A.; Schoder, H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 171 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. BASELINE METABOLIC TUMOR VOLUME IS AN INDEPENDENT PROGNOSTIC FACTOR FOR RELAPSED AND REFRACTORY HODGKIN LYMPHOMA PATIENTS RECEIVING PET‐ADAPTED SALVAGE THERAPY WITH BRENTUXIMAB VEDOTIN AND AUGMENTED ICE. (June 2017) Authors: Moskowitz, A.J.; Schöder, H.; Gavane, S.; Thoren, K.L.; Fleisher, M.; Yahalom, J.; McCall, S.J.; Fox, S.Y.; Gerecitano, J.; Grewal, R.; Hamlin, P.A.; Horwitz, S.; Kumar, A.; Matasar, M.; Ni, A.; Noy, A.; Palomba, M.L.; Perales, M.; Portlock, C.S.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 36 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. DOSE AND/OR VOLUME REDUCTION USING CONSOLIDATION VOLUME RADIATION THERAPY (CVRT) LOWERS DOSE TO HEART AND LUNGS IN EARLY‐STAGE HODGKIN LYMPHOMA PATIENTS WITH BULKY DISEASE. (June 2017) Authors: Yang, J.C.; Kumar, A.; Chapman, K.L.; Burleson, S.; Huang, C.; Constine, L.S.; Hoppe, R.T.; Dandapani, S.; Straus, D.J.; Moskowitz, C.H.; Yahalom, J. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 175 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. IMPACT OF PET IMAGING AND HISTOLOGIC TRANSFORMATION ON THE PROGNOSIS OF EARLY DISEASE PROGRESSION IN FOLLICULAR LYMPHOMA. (12th June 2019) Authors: Batlevi, C.L.; Sha, F.; Alperovich, A.; Ni, A.; Smith, K.; Ying, Z.; Hamlin, P.; Horwitz, S.M.; Kumar, A.; Matasar, M.; Moskowitz, A.J.; Moskowitz, C.H.; Noy, A.; Palomba, M.L.; Portlock, C.; Straus, D.; Boccomini, C.; Tucci, A.; Zelenetz, A.D.; Seshan, V.E. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 152 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. INTERIM RESULTS FROM a PHASE 1/2 STUDY OF BRENTUXIMAB VEDOTIN IN COMBINATION WITH NIVOLUMAB IN PATIENTS WITH RELAPSED OR REFRACTORY HODGKIN LYMPHOMA. (June 2017) Authors: Herrera, A.F.; Moskowitz, A.J.; Bartlett, N.L.; Vose, J.M.; Ramchandren, R.; Feldman, T.A.; Lacasce, A.S.; Ansell, S.M.; Moskowitz, C.H.; Fenton, K.; Ogden, C.; Taft, D.; Zhang, Q.; Kato, K.; Campbell, M.; Advani, R.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 85 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. PEMBROLIZUMAB MONOTHERAPY IN PATIENTS WITH PRIMARY REFRACTORY CLASSICAL HODGKIN LYMPHOMA: SUBGROUP ANALYSIS OF THE PHASE 2 KEYNOTE‐087 STUDY. (June 2017) Authors: Zinzani, P.L.; Fanale, M.A.; Chen, R.; Armand, P.; Johnson, N.; Brice, P.; Radford, J.; Ribrag, V.; Molin, D.; Vassilakopoulos, T.P.; Tomita, A.; von Tresckow, B.; Shipp, M.A.; Zhang, Y.; Balakumaran, A.; Moskowitz, C.H. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 136 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
8. PHASE 1B KEYNOTE‐013 STUDY OF PEMBROLIZUMAB IN PATIENTS WITH CLASSIC HODGKIN LYMPHOMA AFTER BRENTUXIMAB VEDOTIN FAILURE: RESULTS OF >4 YEARS OF FOLLOW‐UP. (12th June 2019) Authors: Zinzani, P.L.; Armand, P.; Ribrag, V.; Michot, J.; Kuruvilla, J.; Zhu, Y.; Farooqui, M.; Nahar, A.; Moskowitz, C.H. Journal: Hematological oncology Issue: Volume 37(2019)Supplement 2 Page Start: 296 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
9. PHASE 1B STUDY OF PEMBROLIZUMAB IN PATIENTS WITH RELAPSED/REFRACTORY PRIMARY MEDIASTINAL LARGE B‐CELL LYMPHOMA (RRPMBCL): UPDATED RESULTS FROM THE KEYNOTE‐013 TRIAL. (June 2017) Authors: Zinzani, P.; Ribrag, V.; Moskowitz, C.H.; Michot, J.; Kuruvilla, J.; Bartlett, N.; Balakumaran, A.; Chatterjee, A.; Chlosta, S.; Shipp, M.A.; Armand, P. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 189 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
10. TIME FROM DIAGNOSIS TO 2ND TREATMENT IS A PROMISING SURROGATE FOR OVERALL SURVIVAL IN PATIENTS WITH ADVANCED STAGE FOLLICULAR LYMPHOMA. (June 2017) Authors: Soumerai, J.D.; Ni, A.; Batlevi, C.; Alperovich, A.; Bantilan, K.S.; Palomba, M.; Gerecitano, J.F.; Noy, A.; Hamlin, P.; Moskowitz, C.H.; Copeland, A.R.; Matasar, M.J.; Drullinsky, P.R.; Hamilton, A.; Horwitz, S.M.; Intlekofer, A.M.; Kumar, A.; Moskowitz, A.; Portlock, C.; Sauter, C. Journal: Hematological oncology Issue: Volume 35(2017)Supplement 2 Page Start: 230 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗